MetaCap

CG Oncology (CGON) vs Vaxcyte (PCVX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CG Oncology (CGON) has outperformed Vaxcyte (PCVX) over the past year, gaining 87.3% versus a gain of 15.9%. Vaxcyte is the larger company by market cap ($8.77 billion vs $7.10 billion), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGON+87.25%PCVX+15.93%
+105%+44%-18%
Nov 21, 20251 yearNov 20, 2026
CGON+126.86%PCVX-13.87%
+137%+37%-63%
Jan 22, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGON versus PCVX key metrics
MetricCGONPCVX
Share price$79.47$55.39
Market cap$7.10B$8.77B
1-day change-2.97%-5.09%
YTD return+91.40%+20.05%
1-year return+87.25%+15.93%
5-year return—+178.90%
EPS (TTM)$-2.76$-8.05
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$4.04M—
Revenue growth (YoY)+254.70%—
Net income (latest FY)$-161.00M$-766.63M
Operating margin-4722.13%—
Net margin-3985.02%—
52-week high$93.95$90.75
52-week low$37.01$42.40
Distance from 52-week high-15.41%-38.96%
Analyst consensusstrong_buynone
Avg. price target upside+38.03%+110.15%
Average volume1.24M2.19M
Shares outstanding89.32M158.30M
Employees142507
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGON has outperformed PCVX by 71.3 percentage points over the past year.

About CG Oncology

CGON stock →

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees

About Vaxcyte

PCVX stock →

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees

CGON vs PCVX FAQ

Which is bigger, CG Oncology or Vaxcyte?

Vaxcyte (PCVX) is larger, with a market capitalization of $8.77B compared with $7.10B for CG Oncology (CGON).

Which stock has performed better over the past year, CGON or PCVX?

CGON returned +87.25% over the past 12 months, compared with +15.93% for PCVX (price return, excluding dividends). Past performance does not predict future results.

Are CG Oncology and Vaxcyte in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons